The US Food and Drug Administration (FDA) has granted breakthrough therapy status to United States-based Bristol-Myers Squibb's Orencia (abatacept) to prevent moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors, it was reported yesterday.
The product is an immunomodulator that disturbs the continuous cycle of T–cell activation, which indicates rheumatoid arthritis (RA).
The FDA designation was granted based on the results of an investigator-initiated trial supported by the company. The phase two study assessed the effect of the product on the prevention of severe acute GvHD, when combined with a standard GvHD prophylactic regimen administered to patients with hematologic malignancies receiving a stem cell transplant from an unrelated, HLA-matched or mismatched donor. It was also approved to decrease signs and symptoms in patients two years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis. In addition, the product was approved to treat adult patients with active psoriatic arthritis.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study